Drug intelligence / Profile preview

HuRicell-Derma

Development stage: Preclinical
Lead developer: Hurimbiocell
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

HuRicell-Derma is an autologous cell therapy candidate developed by Hurimbiocell for the treatment of vitiligo. The therapy utilizes adipose-derived stem cells (ADSCs) in combination with melanin transplantation technology to restore skin pigmentation in affected areas. Developed in collaboration with Dong-guk University, the product aims to repopulate depigmented skin with functional melanin-producing cells by leveraging the regenerative potential of stem cells to support melanocyte survival and activity. HuRicell-Derma has completed nonclinical GLP studies and is progressing toward Phase 1/2a clinical trials in South Korea, with support from the Ministry of Health and Welfare (MOHW).

Brand names: HuRicell-Derma
Other names: HuRicell-Derma

Beyond the preview

Go deeper on HuRicell-Derma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuRicell-Derma.

Explore the full profile